SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 47714779.
  • 2
    Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 1183311841.
  • 3
    Standring DN, Patty A, Chapron C, van Doorn L, Belanger B, Brown NA, et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the International GLOBE Trial (Abstract). Digestive Disease Week, Washington, DC, 2007.
  • 4
    Delaney WEt. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother 2007; 59: 827832.
  • 5
    Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. Emergence of a novel lamivudine-resistant hepatitis b virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006; 50: 38673874.
  • 6
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 7
    Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 11981209.
  • 8
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.
  • 9
    Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 20392049.
  • 10
    Colonno R, Rose R, Pokornowski K, Baldick C, Eggers B, Xu D, et al. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients [Abstract]. J Hepatol 2007; 46: s295.
  • 11
    Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902911.
  • 12
    Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose R, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genoptyic resistance and patient virologic response. J Hepatol 2008. In press.
  • 13
    Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 34983507.
  • 14
    Christman JK, Gerber M, Price PM, Flordellis C, Edelman J, Acs G. Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA. Proc Natl Acad Sci U S A 1982; 79: 18151819.
  • 15
    Fallows DA, Goff SP. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J Virol 1995; 69: 30673073.
  • 16
    Melegari M, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1 deletion mutants. Virology 1994; 199: 292300.
  • 17
    Baraclude prescribing information. Available at http://www.fda.gov/cder/foi/label/2007/021797s003,021798s003lbl.pdf. Accessed 2007.
  • 18
    Walsh A, Langley D, Rose R, Levine S, Pokornowski K, Yu C, et al. Mechanistic characterization of entecavir resistance in lamivudine resistant hepatitis B virus. Antiviral Res 2006; 70: A36.
  • 19
    Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, et al. Inhibition of hepatitis B virus polymerase by Entecavir. J Virol 2007; 81: 39924001.
  • 20
    Tenney D, Langley DR, Oliver AJ, Rose R, Levine SM, Yu CF, et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase [Abstract]. HEPATOLOGY 2004; 40: 245A.
  • 21
    Zoulim F. Hepatitis B virus resistance to entecavir in nucleoside naive patients: does it exist? HEPATOLOGY 2006; 44: 14041407.
  • 22
    Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, et al. The rtL80I substitution in the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51: 22852292.
  • 23
    Pallier C, Castera L, Soulier A, Hezode C, Nordmann P, Dhumeaux D, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 2006; 80: 643653.